How similar are the treatment responses to biosimilars in patients with psoriasis? A systematic review of statistical margins in comparative clinical trials.
作者信息
Wan Marilyn T, Strober Bruce E, Wu Jashin J, Shin Daniel B, Gelfand Joel M
机构信息
Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
University of Connecticut Health Center, Farmington, Connecticut.
出版信息
J Am Acad Dermatol. 2017 Sep;77(3):569-572. doi: 10.1016/j.jaad.2017.05.032.
Abstract
摘要
相似文献
1
How similar are the treatment responses to biosimilars in patients with psoriasis? A systematic review of statistical margins in comparative clinical trials.银屑病患者对生物类似药的治疗反应有多相似？对比较性临床试验中统计学差异的系统评价。
J Am Acad Dermatol. 2017 Sep;77(3):569-572. doi: 10.1016/j.jaad.2017.05.032.
2
Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.在类风湿关节炎和银屑病试验中，原研 TNF 抑制剂和生物类似药的疗效和安全性结局：系统文献回顾。
BioDrugs. 2018 Jun;32(3):193-199. doi: 10.1007/s40259-018-0283-4.
3
Etanercept and efalizumab for the treatment of psoriasis: a systematic review.依那西普和依法利珠单抗治疗银屑病：一项系统评价。
Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. doi: 10.3310/hta10460.
4
A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?美国生物类似药批准的系统评价：FDA 需要什么证据，制造商如何回应？
J Manag Care Spec Pharm. 2017 Dec;23(12):1234-1244. doi: 10.18553/jmcp.2017.23.12.1234.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
6
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis.肿瘤生物类似药的比较安全性概况：系统评价与网状Meta分析
BioDrugs. 2023 Mar;37(2):205-218. doi: 10.1007/s40259-023-00576-8. Epub 2023 Feb 2.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
8
A Review of Topical Roflumilast for the Treatment of Plaque Psoriasis.外用罗氟司特治疗斑块状银屑病的综述
Ann Pharmacother. 2023 Aug;57(8):966-969. doi: 10.1177/10600280221137750. Epub 2022 Nov 24.
9
Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis.不同类别生物制剂治疗银屑病的实际每位缓解者成本
Acta Derm Venereol. 2025 Jun 18;105:adv42767. doi: 10.2340/actadv.v105.42767.
10
Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence.用于癌症治疗的生物类似药：已发表证据的系统评价
BioDrugs. 2017 Feb;31(1):1-36. doi: 10.1007/s40259-016-0207-0.
引用本文的文献
1
Assessing the compliance of systematic review articles published in leading dermatology journals with the PRISMA statement guidelines: A systematic review.评估发表于顶尖皮肤病学杂志的系统评价文章对PRISMA声明指南的遵循情况：一项系统评价。
JAAD Int. 2020 Sep 7;1(2):157-174. doi: 10.1016/j.jdin.2020.07.007. eCollection 2020 Dec.
2
Head-to-head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences.系统性银屑病治疗的头对头试验：研究设计和最大可接受治疗差异的系统评价。
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):42-55. doi: 10.1111/jdv.15174. Epub 2018 Aug 5.
本文引用的文献
1
Biosimilars for psoriasis: clinical studies to determine similarity.银屑病生物类似药：用于确定相似性的临床研究。
Br J Dermatol. 2017 Jul;177(1):23-33. doi: 10.1111/bjd.15067. Epub 2017 May 28.
2
Biosimilars for psoriasis: preclinical analytical assessment to determine similarity.银屑病生物类似药：用于确定相似性的临床前分析评估。
Br J Dermatol. 2016 Feb;174(2):282-6. doi: 10.1111/bjd.14267. Epub 2015 Dec 30.
3
Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know.银屑病的生物制药和生物类似药：皮肤科医生需要了解的知识。
J Am Acad Dermatol. 2012 Feb;66(2):317-22. doi: 10.1016/j.jaad.2011.08.034.
Zotero 插件